SUBSTITUTED 1H-PYRROLOPYRIDINONE DERIVATIVES AS KINASE INHIBITORS

The present invention provides novel substituted 1H-Pyrrolopyridinone derivatives of formula (1) as protein kinase inhibitors, in which R1, R2, R3, R4, R5, R6 and 'p' have the meanings given in the specification, and pharmaceutically acceptable salts thereof that are useful in the treatmen...

Full description

Saved in:
Bibliographic Details
Main Authors BORUAH, ANIMA, HOSAHALLI, SUBRAMANYA, CHITTY VENKATA, SRIKANTH, PANIGRAHI, SUNIL KUMAR
Format Patent
LanguageEnglish
French
Published 21.08.2014
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The present invention provides novel substituted 1H-Pyrrolopyridinone derivatives of formula (1) as protein kinase inhibitors, in which R1, R2, R3, R4, R5, R6 and 'p' have the meanings given in the specification, and pharmaceutically acceptable salts thereof that are useful in the treatment and prevention in diseases or disorder, in particular their use in diseases or disorder where there is an advantage in inhibiting kinase enzyme, more particularly BTK enzyme. The present invention also provides methods for synthesizing and administering the kinase inhibitor compounds. The present invention also provides pharmaceutical formulations comprising at least one of the kinase inhibitor compounds together with a pharmaceutically acceptable carrier, diluent or excipient therefor. La présente invention concerne de nouveaux dérivés de 1H-pyrrolopyridinone substitués de formule (1) en tant qu'inhibiteurs de protéines kinases, dans laquelle R1, R2, R3, R4, R5, R6 et 'p' ont les significations proposées dans la spécification, et leurs sels pharmaceutiquement acceptables qui sont utiles dans le traitement et la prévention de maladies ou de troubles, en particulier leur utilisation dans des maladies ou des troubles pour lesquels l'inhibition d'une enzyme kinase est avantageuse, plus particulièrement l'inhibition de l'enzyme BTK. La présente invention concerne en outre des procédés de synthèse et d'administration des composés inhibiteurs de kinase. La présente invention concerne en outre des formulations pharmaceutiques comprenant au moins un composé inhibiteur de kinase conjointement à un vecteur, un diluant ou un excipient, pharmaceutiquement acceptables, pour celles-ci.
Bibliography:Application Number: WO2014IB58881